CCL2 and diffuse large B-cell lymphoma: A study showed that CREBBP/EP300 mutation in DLBCL patients had higher CCL2 expression, and tumor progression was induced by TAMs throughout the FBXW7-NOTCH-CCL2/CSF1 axis [88].